艾米替诺福韦治疗慢性乙型肝炎患者的临床效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (487 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Tenofovir Amibufenamide(TMF)in the treatment of chronic hepatitis B (CHB).Methods A total of 120 CHB patients admitted to the Second Affiliated Hospital of Yichun University from May to October 2022 were selected as the study objects.According to their treatment experience,the patients were divided into initial CHB group(n=38)and retreated CHB group(n=82),and both groups were treated with TMF.The virological response of the two groups of patients was compared,and the proportion of alanine transaminase(ALT)returned to normal was counted in all patients,and the changes of creatinine(Cr),total cholesterol (TC),triglyceride(TG),serum cystatin C (CysC)and estimated glomerular filtration rate(eGFR)were observed.Results The hepatitis B virus DNA(HBV DNA)level of the two groups after 12 and 24 weeks of treatment was lower than those before treatment,and the proportion of complete virological response of the initial CHB group at 24 weeks of treatment was higher than that at 12 weeks of treatment,the differences were statistically significant(P＜0.05).Complete virological response was achieved in 40 patients with retreated CHB before TMF treatment,and the proportion of complete virological response in the remaining 42 patients after 12 and 24 weeks of treatment was not statistically significant(P＞0.05).The proportion of ALT returning to normal was 40.00%at 12 weeks and 78.33%at 24 weeks.There were no significant differences in the levels of Cr,TC,TG,CysC and eGFR of all patients after 24 weeks of treatment and before treatment (P＞0.05).Conclusion TMF treatment of CHB patients has a good early effect,patients with renal function and lipid indexes have no adverse safety effects,but the long-term effect remains to be seen.

Key words： Chronic hepatitis B Tenofovir Amibufenamide Antiviral therapy Virological response Alanine transaminase Renal function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I15/24

[1]	中华医学会感染病学分会，中华医学会肝病学分会.慢性乙型肝炎防治指南（2019 年版）[J].临床肝胆病杂志，2019，35（12）：2648-2669.
[2]	Global progress report on HIV，viral hepatitis and sexually transmitted infections，2021.Accountability for the global health sector strategies 2016_2021：actions for impact[EB/OL].[2023_06_02].https://apps.who.int/iris/bitstream/handle/10665/342 80 z8/9789240030985-eng.pdf.
[3]	Liu J，Liang W，Jing W，et al.Countdown to 2030：eliminating hepatitis B disease，China[J].Bull World Health Organ，2019，97（3）：230-238.
[4]	中华医学会肝病学分会.扩大慢性乙型肝炎抗病毒治疗的专家意见[J].中华肝脏病杂志，2022，30（2）：131-136.
[5]	罗秋敏，陈佳，李智鹏，等.慢性乙型肝炎抗病毒治疗新进展[J].广东医学，2022，43（7）：843-848.
[6]	Terrault NA，Lok ASF，Mcmahon BJ，et al.Update on prevention，diagnosis，and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J].Hepatology，2018，67（4）：1560-1599.
[7]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2022 年版）[J].中华传染病杂志，2023，41（1）：3-28.
[8]	祝达，郭玉杰，陈丽文，等.核苷类似物治疗慢性乙型肝炎至病毒学应答后谷丙转氨酶异常的因素分析[J].中国医药科学，2022，12（3）：20-23，50.
[9]	张宇，柳丽娟，杨惠安，等.乙型肝炎核心抗体对慢性乙型肝炎初治患者显著纤维化的预测价值[J].中国医药科学，2023，13（15）：4-7.
[10]	刘莲，王晨雪，崔书彦，等.拉米夫定联合复方甘草酸苷、小柴胡汤治疗慢性乙型肝炎疗效观察[J].现代中西医结合杂志，2020，29（36）：4042-4045.
[11]	安选，刘书宏，夏莉娜，等.HBeAg/HBeAb 双阳性慢性乙型肝炎患者不同抗病毒方案疗效及临床转归分析[J].第三军医大学学报，2022，44（2）：162-167.
[12]	邹东花，秘建威，李玉苓，等.阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T 单位点突变的慢性乙型肝炎患者疗效初步研究[J].实用肝脏病杂志，2022，25（3）：331-334.
[13]	李君，邓旭平，王晨.富马酸替诺福韦酯与恩替卡韦治疗慢性乙型肝炎的疗效及其对炎症因子的影响[J].川北医学院学报，2022，37（7）：928-931.
[14]	卢嘉惠，张丛楠，何鹏园，等.富马酸丙酚替诺福韦治疗慢性乙型肝炎合并脂肪肝的疗效及安全性[J].肝脏，2022，27（8）：858-862，867.
[15]	李金卓，李晓云，严汝庆，等.慢性乙型肝炎抗病毒治疗药物应用新进展[J].临床合理用药杂志，2022，15（26）：178-181.
[16]	中华医学会感染病学分会，中华医学会肝病学分会.慢性乙型肝炎临床治愈（功能性治愈）专家共识[J].中华肝脏病杂志，2019，27（8）：594-603.
[17]	任珊，郑素军.《2021 年亚太肝病学会慢性乙型肝炎患者停用核苷（酸）类似物指导意见》摘译[J].临床肝胆病杂志，2022，38（1）：78-80.
[18]	程能能.我国首个原研口服抗HBV 药物TMF 结构优势解读_神奇的甲基化[J].肝脏，2021，26（12）：1303-1305.
[19]	Liu Z，Jin Q，Zhang Y，et al.Randomised clinical trial：48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B[J].Aliment Pharmacol Ther，2021，54（9）：1134-1149.
[20]	李亚萍，崔丹丹，苟国娥，等.艾米替诺福韦治疗慢性乙型肝炎患者的早期疗效：一项真实世界多中心临床研究[J].肝脏，2023，28（1）：100-104.
[21]	Liu Z，Jin Q，Zhang Y，et al.96-Week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatits B patients[J/OL].J Clin Transl Hepatol，2023，11（3）：649-660.
[22]	张丹蕾，徐静.艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究[J].实用肝脏病杂志，2023，26（3）：336-339.